Investment Oversight that Considers Financial Returns and Social Impact

GHIF investments are subject to the approval of an independent Investment Committee and a Charitability Oversight Committee. In addition, the Fund leverages the expertise of its investor base via an Investor Advisory Committee and a Scientific Advisory Committee. Collectively, these committees constitute a robust investment review and governance structure for the Fund.

Loading...

The Global Health Investment Corporation (GHIC) is a non-profit established to provide long-term funding for global health research and development through financing vehicles such as the Global Health Investment Fund. The GHIC is the Managing Member of the Fund and is a US-registered 501(c)(4).  It is governed by an independent board of directors who bring diverse expertise from backgrounds in the pharmaceutical industry, venture capital, investment banking, philanthropy and international development.

Labeeb Abboud, Chairman of the GHIC Board
Labeeb Abboud, Chairman of the GHIC BoardSenior Vice President & General Counsel at IAVI
Bill Greene, Director
Bill Greene, DirectorPresident and CEO of Iconic Therapeutics, Inc.
Wolfgang Bichmann, Director
Wolfgang Bichmann, DirectorFormer Head of Sector and Policy Division - Health, Education and Social Protection at KfW
Andrin Oswald, Director
Andrin Oswald, DirectorDirector, Life Sciences Partnerships at the Bill & Melinda Gates Foundation
George Wellde, Director
George Wellde, DirectorFormer Vice Chairman of the Securities Division at Goldman, Sachs & Co.

How GHIF Works

GHIF Oversight Committees and Disclosures

  • Peter Singer, Chief Executive Officer, Grand Challenges Canada
  • Grethe Petersen, Director, Health, Children’s Investment Fund Foundation
  • Max Schwendner, Vice President, Private Investments, JPMorgan Chase & Co.
  • Jeffrey Haines, Head, Deal Finance and M&A, Worldwide Business Development, GlaxoSmithKline
  • Chris McCahan, Chief Investment Officer – Consumer & Social Services, International Finance Corporation
  • David Glatt, Executive Director and New Products Leader – Infectious Diseases, Merck
  • Jonathan Dean, Portfolio Manager, AXA Investment Managers
  • Joseph Belisle, Senior Director of Operations – Corporate Responsibility, Pfizer
The Charitability Oversight Committee reviews compliance with charitable restrictions and Program-Related Investment (PRI) requirements, in addition to monitoring the social impact of GHIF investments.

  • Andrew Farnum, Director of Program-Related Investments, Bill & Melinda Gates Foundation
  • David Shoultz, Global Program Leader, Drug Development and Devices and Tools, PATH
  • Janice Culpepper, Senior Program Officer, Bill & Melinda Gates Foundation
  • Keith Matthews, Deputy General Counsel, Bill & Melinda Gates Foundation
  • Peter Singer, Chief Executive Officer, Grand Challenges Canada
  • Andrea Gaius-Obaseki, Project Manager – Health, Education, Social Protection (LAB2), KfW Development Bank – Germany
  • Zero Akyol, Program Manager – Unit for Global Social Development, Swedish International Development Cooperation Agency
The Scientific Advisory Committee provides scientific and technical guidance to the Global Health Investment Fund, with representation from the Bill & Melinda Gates Foundation and some of the senior-most executives from the Fund’s strategic investors.

  • Trevor Mundel, President of Global Health, Bill & Melinda Gates Foundation
  • Bill Gruber, Senior Vice President of Vaccine Clinical Research and Development, Pfizer
  • Moncef Slaoui, Chairman Worldwide Research & Development, GlaxoSmithKline
  • Roger Perlmutter, Executive Vice President and President of Merck Research Laboratories, Merck
As a 501(c)(4) non-profit organization under the US tax code, the Global Health Investment Corporation publicly discloses its annual Form 990 as filed with the Internal Revenue Service. Recent annual filings can be downloaded for the years listed below.